Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a, First-in-human, Open-label, Multicenter, Dose Escalation Study of MP0533 in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

NCT05673057 is registered in ClinicalTrials.gov with Molecular Partners AG as lead sponsor.

NCT NCT05673057
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05673057 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a, First-in-human, Open-label, Multicenter, Dose Escalation Study of MP0533 in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Lead sponsor
Molecular Partners AG
Phase
Phase 1
Overall status
Completed
Start date
December 29, 2022
Completion date
September 14, 2026
Enrollment
80 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

acute, leukemia, myeloid, newly diagnosed